Identifying Neurobiological Markers in Obsessive–Compulsive Disorder: A Study Protocol for a Cross-Sectional Study in Subgroups of Differing Phenotype

• Published in: Applied sciences Vol. 13; no. 12; p. 7306
• Main Authors: Paribello, Pasquale, Carpiniello, Bernardo, Murgia, Roberto, Porcheddu, Antonio Andrea, El-Kacemi, Sabrina, Pinna, Marco, Contu, Martina, Costa, Giulia, Barbarossa, Rossella, Sanna, Egea, Carucci, Sara, Zuddas, Alessandro, Fadda, Paola, Dedoni, Simona, Siddi, Carlotta, Congiu, Patrizia, Figorilli, Michela, Fanzecco, Michela, Puligheddu, Monica, Gagliano, Antonella, Pinna, Federica, Scherma, Maria, Manchia, Mirko
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01-06-2023
• Subjects: Adults; Age; Biomarkers; Brain-derived neurotrophic factor; Comorbidity; Comparative analysis; Cross-sectional studies; Drug resistance; Drug therapy; EEG; Electroencephalography; Ethylenediaminetetraacetic acid; Genetic aspects; Health services; Heterogeneity; Hypotheses; Inflammation; Medical research; Medicine, Experimental; Mental disorders; Mental illness; Neurobiology; Neuropsychology; Obsessive compulsive disorder; Pediatrics; Phenotypes; polysomnography; Sleep; Sleep disorders; Subgroups
• DOI: 10.3390/app13127306
• EISSN: 2076-3417

Obsessive–compulsive disorder (OCD) represents a frequent and highly disabling mental disorder. Past attempts to characterize different disease subgroups focused on the time of onset (late vs. early onset), presence of insight (poor insight), and post-infectious forms (pediatric acute-onset neuropsychiatric syndrome, PANS). Each subgroup may be associated with a differing impact on cognition, functioning, sleep quality, and treatment response profile. Certain lines of evidence suggest brain-derived neurotrophic factor (BDNF) levels may differ between individuals living with OCD as compared with controls, but there is a lack of evidence on the variation of BDNF levels in OCD subgroups. Lastly, the potential of assessing inflammatory states, electroencephalogram, and polysomnography to characterize these subtypes has been hardly explored. Estimates of drug-resistance rates indicate that 20% and up to 65% of affected adults and up to 35% of the pediatric population may not benefit from pharmacological treatments. At least part of the variability in treatment response could depend on the underlying biological heterogeneity. In the present project, we aim to increase the accuracy in characterizing the phenotypical and biological signature for the different OCD subtypes through clinical, cognitive, and sleep markers, along with other possible markers that may be biologically plausible.